版本:
中国

BRIEF-FDA grants priority review to Merck's supplemental marketing application for Keytruda

May 23 Merck & Co Inc-

* FDA grants priority review to Merck’S supplemental biologics license application (sbla) for Keytruda® (pembrolizumab) for treatment of recurrent or advanced gastric or gastroesophageal junction adenocarcinoma

* Merck & Co Inc - fda granted priority review with a pdufa, or target action, date of sept. 22, 2017

* Merck & Co -application submitted seeks approval for keytruda monotherapy in previously treated patients at 200 mg dose administered intravenously every 3 weeks Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐